In 2015, Pompe disease became the first lysosomal storage disorder to be recommended for universal newborn screening by the Secretary of the U.S. Department of Health and Human Services. Newborn screening for Pompe has been implemented in 20 states and several countries across the world. The rates of later-onset disease phenotypes for Pompe and pseudodeficiency alleles are higher than initially anticipated, and these factors must be considered during Pompe disease newborn screening.
This report presents an overview of six years of data from the Missouri State Public Health Laboratory for Pompe disease newborn screening and follow-up.
Authors: Tracy L. Klug, Lori B. Swartz, Jon Washburn, Candice Brannen, and Jami L. Kiesling
International Journal of Neonatal Screening. 2020, 6(1), 11; https://doi.org/10.3390/ijns6010011